Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Circulation · 2023
DOI: 10.1161/circulationaha.121.057844 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Circulation, 2023. Verfasst von Truman J Milling und 17 weiteren Autor:innen. Beteiligte Einrichtung: Seton Dell Medical School Stroke Institute, Dell Medical School, University of Texas at Austin (T.J.M.). Hauptthemen laut MEDLINE: Hemostatics, Thrombosis. Die Arbeit wurde bisher 162-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented.
Methods
Patients with acute major bleeding within 18 hours of FXa inhibitor administration were enrolled. Co-primary end points were anti-FXa activity change from baseline during andexanet alfa treatment and excellent or good hemostatic efficacy, defined by a scale used in previous reversal studies, at 12 hours. The efficacy population included patients with baseline anti-FXa activity levels above predefined thresholds (≥75 ng/mL for apixaban and rivaroxaban, ≥40 ng/mL for edoxaban, and ≥0.25 IU/mL for enoxaparin; reported in the same units used for calibrators) who were adjudicated as meeting major bleeding criteria (modified International Society on Thrombosis and Haemostasis definition). The safety population included all patients. Major bleeding criteria, hemostatic efficacy, thrombotic events (stratified by occurring before or after restart of either prophylactic [ie, a lower dose, for prevention rather than treatment] or full-dose oral anticoagulation), and deaths were assessed by an independent adjudication committee. Median endogenous thrombin potential at baseline and across the follow-up period was a secondary outcome.
Results
There were 479 patients enrolled (mean age, 78 years; 54% male; 86% White); 81% were anticoagulated for atrial fibrillation, and the median time was 11.4 hours since last dose, with 245 (51%) on apixaban, 176 (37%) on rivaroxaban, 36 (8%) on edoxaban, and 22 (5%) on enoxaparin. Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%]). In evaluable apixaban patients (n=172), median anti-FXa activity decreased from 146.9 ng/mL to 10.0 ng/mL (reduction, 93% [95% CI, 94–93]); in rivaroxaban patients (n=132), it decreased from 214.6 ng/mL to 10.8 ng/mL (94% [95% CI, 95–93]); in edoxaban patients (n=28), it decreased from 121.1 ng/mL to 24.4 ng/mL (71% [95% CI, 82–65); and in enoxaparin patients (n=17), it decreased from 0.48 IU/mL to 0.11 IU/mL (75% [95% CI, 79–67]). Excellent or good hemostasis occurred in 274 of 342 evaluable patients (80% [95% CI, 75–84]). In the safety population, thrombotic events occurred in 50 (10%) patients; in 16 patients, these occurred during treatment with prophylactic anticoagulation that began after the bleeding event. No thrombotic episodes occurred after oral anticoagulation restart. Specific to certain populations, reduction of anti-FXa activity from baseline to nadir significantly predicted hemostatic efficacy in patients with intracranial hemorrhage (area under the receiver operating characteristic curve, 0.62 [95% CI, 0.54–0.70]) and correlated with lower mortality in patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Seton Dell Medical School Stroke Institute, Dell Medical School, University of Texas at Austin (T.J.M.).
- Department of Internal Medicine and Radboud Institute of Health Sciences, Nijmegen, the Netherlands (S.M.).
- Population Health Research Institute (L.X., A.S., S.J.C.), McMaster University, Hamilton, Ontario, Canada.
- Alexion, AstraZeneca Rare Disease, Boston, MA (B.K.).
- Departments of Clinical Neurosciences and Radiology, Cumming School of Medicine, University of Calgary, Alberta, Canada (A.D.).
- Department of Medicine (J.W.E., M. Crowther), McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Truman J Milling, Saskia Middeldorp, Andrew Demchuk, John W Eikelboom, Peter Verhamme, Alexander T Cohen, Jose Lopez-Sendon, Ashkan Shoamanesh, Stuart J Connolly
Zitieren
APA
Milling, T. J., Middeldorp, S., Xu, L., Koch, B., Demchuk, A., Eikelboom, J. W., Verhamme, P., Cohen, A. T., Beyer-Westendorf, J., Gibson, C. M., Lopez-Sendon, J., Crowther, M., Shoamanesh, A., Coppens, M., Schmidt, J., Albaladejo, P., Connolly, S. J., & ANNEXA-4 Investigators (2023). Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. https://doi.org/10.1161/circulationaha.121.057844
Vancouver
Milling TJ, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 2023. doi:10.1161/circulationaha.121.057844
BibTeX
@article{Milling2023,
author = {Milling, Truman J and Middeldorp, Saskia and Xu, Lizhen and Koch, Bruce and Demchuk, Andrew and Eikelboom, John W and Verhamme, Peter and Cohen, Alexander T and Beyer-Westendorf, Jan and Gibson, C Michael and Lopez-Sendon, Jose and Crowther, Mark and Shoamanesh, Ashkan and Coppens, Michiel and Schmidt, Jeannot and Albaladejo, Pierre and Connolly, Stuart J and ANNEXA-4 Investigators, ANNEXA-4 Investigators},
title = {Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.121.057844}
}
EUVIMED